STAT Plus: How does Biogen move beyond its Alzheimer’s drug blowup? Listen for the clues
RUBY WALLAU FOR STAT
On this week's earnings call, investors will be listening for what, if anything, management says about the biotech’s path forward.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario